Ng Deborah H L, Choy Chiaw Yee, Chan Yi-Hao, Young Barnaby E, Fong Siew-Wai, Ng Lisa F P, Renia Laurent, Lye David C, Chia Po Ying
National Centre for Infectious Diseases, Singapore.
Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore.
Open Forum Infect Dis. 2020 Aug 24;7(9):ofaa375. doi: 10.1093/ofid/ofaa375. eCollection 2020 Sep.
Prolonged fever is associated with adverse outcomes in dengue viral infection. Similar fever patterns are observed in COVID-19 with unclear significance.
We conducted a hospital-based case-control study of patients admitted for COVID-19 with prolonged fever (fever >7 days) and saddleback fever (recurrence of fever, lasting <24 hours, after defervescence beyond day 7 of illness). Fever was defined as a temperature of ≥38.0°C. Cytokines were determined with multiplex microbead-based immunoassay for a subgroup of patients. Adverse outcomes were hypoxia, intensive care unit (ICU) admission, mechanical ventilation, and mortality.
A total of 142 patients were included in the study; 12.7% (18/142) of cases had prolonged fever, and 9.9% (14/142) had saddleback fever. Those with prolonged fever had a median duration of fever (interquartile range [IQR]) of 10 (9-11) days for prolonged fever cases, while fever recurred at a median (IQR) of 10 (8-12) days for those with saddleback fever. Both prolonged (27.8% vs 0.9%; < .01) and saddleback fever (14.3% vs 0.9%; = .03) were associated with hypoxia compared with controls. Cases with prolonged fever were also more likely to require ICU admission compared with controls (11.1% vs 0.9%; = .05). Patients with prolonged fever had higher induced protein-10 and lower interleukin-1α levels compared with those with saddleback fever at the early acute phase of disease.
Prolonged fever beyond 7 days from onset of illness can identify patients who may be at risk of adverse outcomes from COVID-19. Patients with saddleback fever appeared to have good outcomes regardless of the fever.
登革病毒感染中,持续发热与不良预后相关。在新型冠状病毒肺炎(COVID-19)中也观察到类似的发热模式,但其意义尚不清楚。
我们开展了一项基于医院的病例对照研究,纳入因COVID-19入院且伴有持续发热(发热超过7天)和鞍背热(热退7天后再次发热,持续时间<24小时)的患者。发热定义为体温≥38.0°C。对部分患者亚组采用基于微珠的多重免疫分析法测定细胞因子。不良预后包括低氧血症、入住重症监护病房(ICU)、机械通气和死亡。
本研究共纳入142例患者;12.7%(18/142)的病例有持续发热,9.9%(14/142)有鞍背热。持续发热患者的发热中位持续时间(四分位间距[IQR])为10(9 - 11)天,鞍背热患者发热复发的中位时间(IQR)为10(8 - 12)天。与对照组相比,持续发热(27.8%对0.9%;<0.01)和鞍背热(14.3%对0.9%;=0.03)均与低氧血症相关。与对照组相比,持续发热的病例也更有可能需要入住ICU(11.1%对0.9%;=0.05)。在疾病的早期急性期,与鞍背热患者相比,持续发热患者的诱导蛋白-10水平较高,白细胞介素-1α水平较低。
发病7天后的持续发热可识别出可能出现COVID-19不良预后的患者。无论发热情况如何,鞍背热患者似乎预后良好。